Recent Updates
Recently added Catalysts

RYZ711

Phase 1

Prostate Cancer (Adenocarcinoma) | Small molecule | Oncology |Bristol-Myers Squibb Company|Trials Updated: Oct 7, 2026

RYZ711 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment116

FDA Designations

No designations recorded

RYZ711 clinical trials

RYZ711 · 1 trial · 6 indications

Phase 1 1
NCT07862582RYZ711 Diagnostic Platform StudyProstate Cancer (Adenocarcinoma)
NOT YET_RECRUITING116 Analytics
PHASE1NOT YET_RECRUITING
RYZ711 Diagnostic Platform Study
Prostate Cancer (Adenocarcinoma)
NCT07862582116
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of AEs, SAEs, and Adverse Events of Special Interest (AESIs)
From informed consent up to 3 months post-RYZ711 PET/CT

Incidence of AEs, SAEs, and AESIs including changes in vital signs, clinical laboratory evaluations, 12-lead ECG, and other safety findings

Concordance Rate of RYZ711 PET/CT Compared with PSMA PET/CT
Up to 3 months post-RYZ711 PET/CT

The concordance rate is defined as the proportion of subjects with per-region correspondence of at least 1 lesion identified on RYZ711 PET/CT and PSMA PET/CT

Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
Cohort 1 - RYZ711EXPERIMENTALHigh-risk localized prostate cancer planned for RP/PLND
Cohort 2 - RYZ711EXPERIMENTALBiochemical recurrence after definitive therapy
Cohort 3 - RYZ711EXPERIMENTALMetastatic disease (mHSPC or mCRPC)

Interventions

NameTypeDescription
RYZ711DRUGRYZ711 PET/CT; PSMA PET/CT
PSMA PET/CTDIAGNOSTIC_TESTRYZ711 PET/CT; PSMA PET/CT
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo

Inclusion Criteria Subjects who meet all of the following criteria are eligible for inclusion in the study: 1. Histologically confirmed adenocarcinoma of the prostate 2. ECOG PS ≤ 2 3. Planned or scheduled PSMA PET/CT scan 4. Cohort 1: Unfavorable intermediate-risk or higher per NCCN 2026 guidelin...

Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Bristol-Myers Squibb Company (BMY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with RCompanies A to ZEvery biotech and pharma company we track